Metolazone and Abilify drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Metolazone (metolazone) and Abilify (aripiprazole). Common drug interactions include chronic kidney disease among females and cardiac failure congestive among males.
The phase IV clinical study analyzes what interactions people have when they take Metolazone and Abilify. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.
What is Metolazone?
Metolazone has active ingredients of metolazone. It is often used in swelling. eHealthMe is studying from 13,411 Metolazone users. Check the latest studies of Metolazone.
What is Abilify?
Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,454 Abilify users. Check the latest studies of Abilify.
40 people who take Metolazone and Abilify together, and have interactions are studied.

What are the common drug interactions of Metolazone and Abilify, by gender? *:
female:
- Chronic kidney disease
- Renal failure (kidney dysfunction)
- Nephrogenic anaemia (anaemia due to kidney disease)
- Glomerulonephritis chronic (long lasting group of conditions that affect parts of the kidneys called glomeruli)
- Renal haematoma (blood collection in kidney)
- Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
- Nephritic syndrome (a collection of signs (known as a syndrome) associated with disorders affecting the kidneys, more specifically glomerular disorders)
- Renal tubular necrosis (death of kidney tubules)
- Arthralgia (joint pain)
- Death
male:
- Cardiac failure congestive
- Anxiety
- Iron deficiency anaemia
- Magnesium deficiency (lack of magnesium)
- Chronic kidney disease
- Dyspnoea exertional (breathlessness or shortness of breath)
- Dystonia (abnormal muscle tone)
- Pulmonary hypertension (increase in blood pressure in the lung artery)
- Acute respiratory failure
- Anhedonia (inability to experience pleasure from activities usually found enjoyable)
What are the common drug interactions of Metolazone and Abilify, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
- Cardiac disorder
- Fall
- Lung disorder (lung disease)
- Malaise (a feeling of general discomfort or uneasiness)
- Spinal fracture (fracture in one of vertebrae)
- Anxiety
- Asthma
- Cardiac failure congestive
- Hypercholesterolaemia (high levels of cholesterol in the blood)
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
20-29:
n/a
30-39:
- Chronic kidney disease
- Nephrogenic anaemia (anaemia due to kidney disease)
- Renal failure (kidney dysfunction)
- Acute left ventricular failure (heart attack)
- Acute respiratory failure
- Agitation (state of anxiety or nervous excitement)
40-49:
- Chronic kidney disease
- Renal failure (kidney dysfunction)
- Chronic left ventricular failure (long lasting functional impairment of left ventricle of heart)
- Dyspepsia (indigestion)
- Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
- Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
- Nephrogenic anaemia (anaemia due to kidney disease)
- Pancreatitis (inflammation of pancreas)
- Pleural effusion (water on the lungs)
- Prerenal failure
50-59:
- Chronic kidney disease
- Nephrogenic anaemia (anaemia due to kidney disease)
- Renal failure (kidney dysfunction)
- Cardiac failure congestive
- Glomerulonephritis chronic (long lasting group of conditions that affect parts of the kidneys called glomeruli)
- Renal haematoma (blood collection in kidney)
- Dyspnoea exertional (breathlessness or shortness of breath)
- Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
- Nephritic syndrome (a collection of signs (known as a syndrome) associated with disorders affecting the kidneys, more specifically glomerular disorders)
- Pulmonary hypertension (increase in blood pressure in the lung artery)
60+:
- Renal failure (kidney dysfunction)
- Chronic kidney disease
- Thrombocytopenia (decrease of platelets in blood)
- Vomiting
- Anaemia (lack of blood)
- Death
- Flatulence (flatus expelled through the anus)
- Headache (pain in head)
- Hypersensitivity
- Influenza like illness
What are the existing conditions these people have? *
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 15 people, 37.50%
- High Blood Cholesterol: 8 people, 20.00%
- High Blood Pressure: 8 people, 20.00%
- Pain: 8 people, 20.00%
- Stress And Anxiety: 6 people, 15.00%
- Blood Pressure Abnormal: 5 people, 12.50%
- Sleep Disorder: 5 people, 12.50%
- Cardiac Disorder: 5 people, 12.50%
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 12.50%
- Insomnia (sleeplessness): 4 people, 10.00%
* Approximation only. Some reports may have incomplete information.
Do you take Metolazone and Abilify?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Metolazone (13,411 reports)
- Abilify (101,454 reports)
Browse all drug interactions of Metolazone and Abilify:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Metolazone:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Abilify:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Metolazone and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Abilify and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
- Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
- Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
- Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
How the study uses the data?
The study uses data from the FDA. It is based on metolazone and aripiprazole (the active ingredients of Metolazone and Abilify, respectively), and Metolazone and Abilify (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Cholestyramine cause Aseptic Necrosis? - 5 seconds ago
- Could Zestril cause Retinitis? - 5 seconds ago
- Could Accupril cause Hydrocele? - 8 seconds ago
- Could Clonidine cause Embolism? - 9 seconds ago
- Could Vyvanse cause Aspartate Aminotransferase Increased? - 14 seconds ago
- Drug interactions of Dilaudid and B12 - 21 seconds ago
- Could Repatha cause Atrial Fibrillation/Flutter? - 24 seconds ago
- Could Monopril cause Drug Maladministration? - 26 seconds ago
- Could Digoxin cause Electrocardiogram Poor R-Wave Progression? - 29 seconds ago
- Could Arixtra cause Breast Cancer Metastatic? - 35 seconds ago